<DOC>
	<DOCNO>NCT02000050</DOCNO>
	<brief_summary>Phase II study up-front chemotherapy neo-adjuvant shortcourse radiotherapy resectable rectal carcinoma . Study Design : Phase II , open-label , single-arm , multi-centre study . STUDY PRODUCT , DOSE , ROUTE , REGIMEN AND DURATION OF ADMINISTRATION : 1 . Neoadjuvant Treatment ( pre-operative chemo-radiotherapy regimen ) : FOLFOX4* 2 cycle ( WK1+WK3 ) - Tomotherapy** ( WK5 ) - FOLFOX4* 2 cycle ( WK7+WK9 ) * Oxaliplatin 85 mg/m2 iv : day 1 Levofolinate 100 mg/m2 iv : day 1-2 5-fluorouracil 400 mg/m2 iv bolus 600 mg/m2 iv infusion 22h : day 1-2 Every cycle last 2 week ( approximately 48 hour treatment infusion 12 day rest ) . ** 25 Gy 5 consecutive fraction , one fraction per day 5 day CTV ( Clinical Target Volume ) isodose 95 % total dose . The treatment plan elaborate work-station dedicate Helicoidal Tomotherapy . The treatment could plan also linear accelerator IGRT-IMRT technique VMAT technique . 2 . Restaging ( week 11 ) 3 . Surgery ( week 12-16 ) Total Mesorectal Excision ( TME ) 4 . End Of Treatment ( week 16-32 ) 5 . Adjuvant therapy ( The maximum interval surgery start adjuvant therapy 8 week ) : 6 . FOLFOX4* 8 cycle ( every 2 week ) Study Duration : 5 year . Enrollment period : 36 month . Treatment period : 8 month . Follow-up : 1 year . NUMBER OF SUBJECTs : · Step A : maximum 6 patient . 6 evaluable patient need assess toxicity . If 1 toxicity result discontinuation treatment observe 6 patient , treatment consider safe ( confidence &gt; 90 % ) . If 2 toxicity result discontinuation treatment 6 patient , study stop safe another type radiotherapy schedule must design . · Step B : total 50 patient require recruit 2 year ( include patient enrolled Step A ) . The goal achieve proportion least 15 % patient complete pathological response new radiochemotherapeutic treatment .</brief_summary>
	<brief_title>Phase II Study Up-front Chemotherapy Neo-adjuvant Short-course Radiotherapy Resectable Rectal Carcinoma ( COLORE )</brief_title>
	<detailed_description>Title : Phase II study up-front chemotherapy neo-adjuvant shortcourse radiotherapy resectable rectal carcinoma . Short Title/Acronym : COLORE Protocol Code : IRST154.01 Phase : 2 Study Design : Phase II , open-label , single-arm , multi-centre study . STUDY PRODUCT , DOSE , ROUTE , REGIMEN AND DURATION OF ADMINISTRATION : 1 . Neoadjuvant Treatment ( pre-operative chemo-radiotherapy regimen ) : FOLFOX4* 2 cycle ( WK1+WK3 ) - Tomotherapy** ( WK5 ) - FOLFOX4* 2 cycle ( WK7+WK9 ) * Oxaliplatin 85 mg/m2 iv : day 1 Levofolinate 100 mg/m2 iv : day 1-2 5-fluorouracil 400 mg/m2 iv bolus 600 mg/m2 iv infusion 22h : day 1-2 Every cycle last 2 week ( approximately 48 hour treatment infusion 12 day rest ) . ** 25 Gy 5 consecutive fraction , one fraction per day 5 day CTV ( Clinical Target Volume ) isodose 95 % total dose . The treatment plan elaborate work-station dedicate Helicoidal Tomotherapy . The treatment could plan also linear accelerator IGRT-IMRT technique VMAT technique . 2 . Restaging ( week 11 ) 3 . Surgery ( week 12-16 ) Total Mesorectal Excision ( TME ) 4 . End Of Treatment ( week 16-32 ) 5 . Adjuvant therapy ( The maximum interval surgery start adjuvant therapy 8 week ) : 6 . FOLFOX4* 8 cycle ( every 2 week ) Study Duration : 5 year . Enrollment period : 36 month . Treatment period : 8 month . Follow-up : 1 year . OBJECTIVES Primary objective : Step A : evaluate feasibility safety chemoradiotherapy regimen . Step B : evaluate proportion patient pathological complete remission combine radio-chemotherapy . Secondary objective ( Step B ) : - To evaluate safety neo-adjuvant treatment - To determine pathological down-staging - To evaluate rate R0 resection - To evaluate sphincter save resection rate - To evaluate median disease free survival overall survival - To evaluate correlation biomarker , pathological response outcome ( auxiliary\subsidiary Biological Study ) NUMBER OF SUBJECT : · Step A : maximum 6 patient . 6 evaluable patient need assess toxicity . If 1 toxicity result discontinuation treatment observe 6 patient , treatment consider safe ( confidence &gt; 90 % ) . If 2 toxicity result discontinuation treatment 6 patient , study stop safe another type radiotherapy schedule must design . · Step B : total 50 patient require recruit 2 year ( include patient enrolled Step A ) . The goal achieve proportion least 15 % patient complete pathological response new radiochemotherapeutic treatment . STATISTICAL METHODOLOGY : The primary analysis perform ITT ( Intention-To-Treat ) population , secondary analysis conduct PP ( Per Protocol ) population . The number percentage treat patient undergo grade 1 4 adverse event ( CTC-AE , version 4.0 ) tabulate ITT PP population . No statistical inference perform . Step A : Patients , tumor characteristic toxicity event observe describe . Step B : The proportion patient pathological Complete Response calculate . Safety profile analyze . OS ( Overall Survival ) DFS ( Disease Free Survival ) estimate Kaplan-Meier method ( Kaplan El , Meier P. , J Am Stat Assoc 1958 ) . No interim analysis perform . The 95 % confidence interval also provide .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<criteria>1 . Patients histologically cytologically confirm diagnosis adenocarcinoma midlow rectum ( within 12 cm anal verge ) 2 . Stage : lowT2N0 , T2N+M0 , T34 N/+M0 ( N+ = ≥ 3 node &gt; 0,5 cm diameter ≥ 1 node &gt; 1 cm diameter ) 3 . Age ≥18 ≤ 80 year 4 . ECOG performance status 01 5 . Patients must normal organ marrow function define : 1 . Leukocytes ≥ 3,000/mL 2 . Absolute neutrophil count ≥ 1,500/mL 3 . Platelets ≥ 100,000/mL 4 . Total bilirubin ≤ 1.5 X ULN 5 . AST ( SGOT ) /ALT ( SGPT ) ≤ 2.5 X ULN 6 . Creatinine ≤ 1.5 X ULN 6 . Female participant child bear potential male participant whose partner child bear potential must willing ensure partner use effective contraception study 3 month thereafter 7 . Participant willing able give inform consent participation study . 1 . Metastatic disease 2 . Patients chemotherapy radiotherapy prior enter study 3 . Acute subacute gastrointestinal occlusion 4 . Participation another clinical trial , investigational agent within 30 day prior study screen 5 . Other know malignant neoplastic disease patient 's medical history diseasefree interval le 5 year ( except previously treat basal cell carcinoma , superficial bladder tumor situ carcinoma uterine cervix ) 6 . History allergic reaction attribute compound similar chemical biological composition drug use study 7 . Uncontrolled concomitant illness , include limited : ongoing active infection ; congestive heart failure ; unstable angina pectoris ; cardiac arrhythmia ; psychiatric illness/social situation would limit compliance study requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>resectable rectal cancer</keyword>
	<keyword>up-front chemotherapy</keyword>
	<keyword>neo-adjuvant short course radiotherapy</keyword>
	<keyword>short course radiotherapy</keyword>
</DOC>